Durgical
EN
Open the app

Treating antibody diseases: IVIG, plasma exchange, B-cell depletion

  • Topic

When the body's own antibodies cause the disease, you can dilute them, wash them out of the blood or shut down the cells that make them.

Updated

What it is

Diseases caused by autoantibodies or alloantibodies (myasthenia gravis, Guillain–Barré syndrome, immune thrombocytopenia, pemphigus, anti-GBM disease) are treated by lowering or neutralising the harmful antibody. Intravenous immunoglobulin (IVIG) both replaces antibody in immunodeficiency and modulates immunity at high doses; plasma exchange physically removes antibodies; B-cell depletion with anti-CD20 stops new production more slowly. Newer drugs block FcRn or complement.

Key facts

  • FcRn normally rescues IgG from degradation, giving IgG its long half-life; flooding or blocking it shortens the life of all IgG, including autoantibodies.
  • In TTP, plasma exchange both removes the anti-ADAMTS13 antibody and supplies the missing enzyme.
  • Glucocorticoids and other immunosuppressants are usually given alongside these treatments to lower new antibody production.

Step by step

  1. Plasma cells secrete IgG; FcRn on endothelium rescues IgG from lysosomes, which is why IgG lasts weeks.
  2. Plasma exchange removes plasma, so circulating IgG and immune complexes fall within days.
  3. IgG then rebounds as plasma cells keep secreting and tissue IgG re-enters the blood, so exchange is a bridge, not a cure.
  4. IVIG floods FcRn and FcRn blockers occupy it, so all IgG, including the autoantibody, is degraded faster.
  5. IVIG also blocks Fc receptors on splenic macrophages, which is why platelets rise quickly in ITP.
  6. Anti-CD20 removes B cells, so new plasma cells stop forming; old plasma cells (CD20⁻) fade over months.

Ways to treat antibody-mediated disease

ApproachHow it worksTypical usesCautions
IVIG (pooled IgG from many donors)Saturates FcRn (faster loss of pathogenic IgG), blocks Fc receptors on macrophages, neutralises antibodies and complementKawasaki disease, immune thrombocytopenia, Guillain–Barré, CIDP, myasthenic crisis; replacement in XLA and CVIDHeadache, aseptic meningitis, thrombosis, kidney injury, haemolysis; anaphylaxis risk with anti-IgA antibodies
Plasma exchangeRemoves plasma with antibodies and immune complexes, replaced with albumin or plasmaMyasthenic crisis, Guillain–Barré, anti-GBM disease, TTP, hyperviscosityNeeds vascular access; hypotension, citrate-related low calcium, loss of clotting factors
Anti-CD20 B-cell depletionKills CD20⁺ B cells; plasma cells are spared, so effect is slowPemphigus, ANCA vasculitis, some myasthenia, neuromyelitis optica, ITPHepatitis B reactivation, infections, rarely PML; poor vaccine responses
FcRn blockersStop IgG recycling so IgG levels fallGeneralised myasthenia gravisLower IgG for all specificities
Complement inhibitorsBlock C5 so antibodies cannot cause complement injuryMyasthenia, neuromyelitis optica, atypical HUS, PNHMeningococcal infection risk: vaccinate first

Clinical notes

  • Kawasaki disease: IVIG early in the illness lowers the risk of coronary artery aneurysms.
  • Patients with selective IgA deficiency may have anti-IgA antibodies and react to blood products or IVIG.
  • Screen for hepatitis B before anti-CD20 therapy.
  • Nursing: infuse IVIG slowly at first and watch for infusion reactions and signs of thrombosis.

Common traps

  • Rituximab clears autoantibodies quickly: it spares CD20-negative plasma cells, so antibody levels fall over months, not days.
  • Plasma exchange is a lasting fix: antibody rebounds within days to weeks unless production is also suppressed.
  • IVIG is the same treatment in CVID and in Kawasaki disease: low-level replacement in CVID, high-level immunomodulation in Kawasaki or ITP.
  • FcRn blockers lower only the harmful antibody: they lower all IgG, so protective antibodies fall too.
  • IVIG is safe in any IgA-deficient patient: those with anti-IgA antibodies can have anaphylaxis to IgA traces in it.

Test yourself

Think of the answer, then tap the question to see it.

A child with Kawasaki disease gets IVIG early in the illness. What complication is it meant to prevent, and why does timing matter?

Coronary artery aneurysms; IVIG damps the vasculitis before the arterial wall is permanently damaged, so late treatment helps less.

Why does anti-CD20 therapy lower autoantibody levels only slowly?

It removes B cells but not long-lived plasma cells, which lack CD20 and keep secreting antibody.

In myasthenic crisis, why is plasma exchange chosen over rituximab?

Exchange removes circulating antibody within days; rituximab only stops new production and takes months to act.

Which vaccination is required before starting a complement C5 inhibitor, and why?

Meningococcal vaccination, because blocking C5 removes the membrane attack complex needed to kill Neisseria.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of immunology

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: Antibody (MedlinePlus, US National Library of Medicine, 2024); Immunodeficiency diseases (MedlinePlus, US National Library of Medicine, 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.